Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism
Compose a Response to This Article
Other responses
No responses have been published for this article.
